Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06337318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 265 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Study sites: 285 to 286
  2. Site details revised at 4 of 285 sites
  3. Site details revised at 4 of 285 sites
  4. Site details revised at 2 of 285 sites
  5. Study sites: 283 to 285
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites revised (283)
  2. Site contacts updated at 1 of 283 sites
  3. Study sites: 276 to 283
  1. Trial sites expanded: 276 → 282 locations Site details revised at 2 of 276 sitesv257 Show 1 more changeShow less
    • Site details revised at 2 of 276 sites
  2. Study sites: 275 to 276v256
  3. Site details revised at 4 of 275 sitesv255
  4. Site details revised at 4 of 275 sitesv254
  5. Site details revised at 5 of 275 sitesv253
  6. Site details revised at 5 of 275 sitesv252
  7. Study sites: 273 to 275v251
  8. Site details revised at 1 of 273 sitesv250
  9. Study sites: 271 to 273v249
  10. Site details revised at 3 of 271 sitesv248
  11. Study sites: 270 to 271v247
  12. Study sites: 269 to 270v246
  13. Site contacts updated at 1 of 269 sitesv245
  14. Study sites: 270 to 269v244
  15. Re-verified, no change to tracked fieldsv243
  16. Study sites revised (270)v242 See this version in full on ClinicalTrials.gov ↗
  17. Site details revised at 2 of 270 sitesv241
  18. Site details revised at 1 of 270 sitesv240
  19. Site details revised at 1 of 270 sitesv239
  20. Site details revised at 1 of 270 sitesv238
  21. Site details revised at 2 of 270 sitesv237
  22. Site details revised at 2 of 270 sitesv236
  23. Study sites: 268 to 270v235
  24. Study sites: 267 to 268v234
  25. Study sites revised (267)v233 See this version in full on ClinicalTrials.gov ↗
  26. Site contacts updated at 1 of 267 sitesv232
  27. Study sites: 266 to 267v231
  28. Re-verified, no change to tracked fieldsv230
  29. Site details revised at 1 of 266 sitesv229
  30. Study sites: 265 to 266v228
  31. Study sites: 264 to 265v227
  32. Site details revised at 7 of 264 sitesv226
  33. Re-verified, no change to tracked fieldsv225
  34. Site details revised at 2 of 264 sitesv224
  35. Site details revised at 1 of 264 sitesv223
  36. Study sites: 262 to 264v222
  37. Study sites: 261 to 262v221
  38. Study sites revised (261)v220 See this version in full on ClinicalTrials.gov ↗
  39. Study sites: 262 to 261v219
  40. Site details revised at 1 of 262 sitesv218
  41. Study sites revised (262)v217 See this version in full on ClinicalTrials.gov ↗
  42. Site details revised at 1 of 262 sitesv216
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Trial Details
NCT Number NCT06337318
Lead Sponsor National Cancer Institute (NCI)
Conditions Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov